Novozymes, a bioinnovation company with a major plant in Roanoke, and Syngenta, one of the world’s leading agricultural companies, today announced an exclusive global marketing and distribution agreement on the microbial-based biofungicide Taegro, a natural solution with multiple modes of action used to combat fungal diseases across various crops.
The companies will join forces to bring Novozymes’ Taegro
to farmers worldwide through Syngenta’s global organization.
matches Syngenta’s global market strength and leading position within
fungicides and integrated solutions with Novozymes’ deep know-how on
sustainable, biobased technologies,” says Thomas Videbæk, Executive Vice
President of Novozymes.
“Using technology developed by Novozymes, Syngenta
will provide farmers all over the world with a biological product to help
sustainably combat fungal diseases in a powerful manner.”
“We're delighted to
enter into another agreement to commercialize a Novozymes technology. Having
worldwide commercial rights for Taegro will further strengthen our ability to
offer high-performing integrated crop solutions,” comments John Atkin, Chief
Operating Officer of Syngenta.
offers a biological solution in the form of a microbial-based fungicide,
based on the naturally occurring Bacillus subtilis bacterium, which is
complementary to existing fungicide technology. It effectively targets fungal
diseases such as Rhizoctonia and Fusarium on fruit and vegetables, and its
application is expected to be expanded to a wider portfolio of broad-acre
crops such as wheat, soy and corn.
Under the terms of
Novozymes and Syngenta will share the task of bringing Taegro
to market. Syngenta will be responsible for sales, marketing and
distribution, while Novozymes will be responsible for production and
registration. Trials are planned to secure data to continue to build on the
current U.S. registration in other regions, following which the two companies
aim for a global rollout.
about the agreement are not being disclosed.